edp-323
Small moleculeexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 29, 2022 (NCT05587478)
Timeline
Indications
Mechanism of action
- Acyl-protein thioesterase 1INHIBITOR
LYPLA1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06917508 | Phase 1 | Mar 13, 2025 | Enanta Pharmaceuticals |
| NCT06847464 | Phase 1 | Jan 27, 2025 | Enanta Pharmaceuticals |
| NCT06170242 | Phase 2 | Nov 20, 2023 | Enanta Pharmaceuticals, hVIVO Services Limited |
| NCT05587478 | Phase 1 | Sep 29, 2022 | Enanta Pharmaceuticals |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Enanta Pharmaceuticals | For profit | 4 | 4 | 2 | 2022 |
| hVIVO Services Limited | For profit | 1 | 0 | 1 | 2023 |
2 organizations
Page 1 / 1